SCHEMBL21783559

SCHEMBL21783559

CC(C)(C)OC(=O)Nc1cc(F)c(S(=O)(=O)Cl)nc1C1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 1/20 0.39
CYP17A1 P05093 1/20 0.36
DGAT1 O75907 2/20 0.36
RORC P51449 5/20 0.35
BRD4 O60885 1/20 0.35
BRD2 P25440 1/20 0.35
BRD3 Q15059 1/20 0.35
CREBBP Q92793 1/20 0.35
ACACB O00763 2/20 0.33
SCN1A P35498 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN8A Q9UQD0 1/20 0.33
AAK1 Q2M2I8 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30045577 1.00 BRAF (0.39) BRAFCYP17A1DGAT1RORCBRD4
SCHEMBL30045766 0.84 BRAF (0.41) BRAFCYP17A1DGAT1RORCBRD4
SCHEMBL21783471 0.84 BRAF (0.41) BRAFCYP17A1DGAT1RORCBRD4
SCHEMBL21783541 0.82 LCK (0.39) BRAFCYP17A1BRD4AAK1CA1
SCHEMBL30046612 0.82 LCK (0.39) BRAFCYP17A1BRD4AAK1CA1
SCHEMBL21777303 0.82 KMT2A (0.33) SCN1ASCN5ASCN8A
SCHEMBL21783561 0.81 BRAF (0.40) BRAFCYP17A1DGAT1RORCBRD4
SCHEMBL21783430 0.80 SCN1A (0.55) SCN1ASCN5ASCN8A
SCHEMBL25027545 0.73 BRD4 (0.40) DGAT1BRD4BRD2BRD3CREBBP
SCHEMBL29361617 0.73 BRD4 (0.40) DGAT1BRD4BRD2BRD3CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112638879-B Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents 泽农医药公司 2024-06-18 CN disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. 2023-05-02 US disclosed
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-04-20 US disclosed
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-05-21 US disclosed
WO-2020047323-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639351-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B BRAF 414/4885CYP17A1 2782/4885DGAT1 2666/4885
US-20200157089-A1 HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN2A, SCN2B BRAF 414/4885CYP17A1 2782/4885DGAT1 2666/4885
US-10981905-B2 Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents SCN1A, SCN2A, SCN2B BRAF 414/4885CYP17A1 2782/4885DGAT1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.